Major depression and bipolar disorder are heterogeneous conditions in which there can be dysregulation of (1) the stress system response, (2) its capacity for counterregulation after danger has passed and (3) the phase in which damaging molecules generated by the stress response are effectively neutralized. The response to stress and depressed mood share common circuitries and mediators, and each sets into motion not only similar affective and cognitive changes, but also similar systemic manifestations. We focus here on two highly interrelated processes, parainflammation and endoplasmic reticulum (ER) stress, each of which can potentially interfere with all phases of a normal stress response in affective illness, including adaptive neuroplastic changes and the ability to generate neural stem cells. Parainflammation is an adaptive response of the innate immune system that occurs in the context of stressors to which we were not exposed during our early evolution, including overfeeding, underactivity, aging, artificial lighting and novel foodstuffs and drugs. We postulate that humans were not exposed through evolution to the current level of acute or chronic social stressors, and hence, that major depressive illness is associated with a parainflammatory state. ER stress refers to a complex program set into motion when the ER is challenged by the production or persistence of more proteins than it can effectively fold. If the ER response is overwhelmed, substantial amounts of calcium are released into the cytoplasm, leading to apoptosis. Parainflammation and ER stress generally occur simultaneously. We discuss three highly interrelated mediators that can effectively decrease parainflammation and ER stress, namely the central insulin, klotho and peroxisome proliferator-activated receptor-g (PPAR-g) systems and propose that these systems may represent conceptually novel therapeutic targets for the amelioration of the affective, cognitive and systemic manifestations of major depressive disorder.
Major depression is a common and complex disorder of geneenvironment interactions, which now represents the major burden of nonfatal disease in several countries, including Australia. In developed countries, major depression represents the second greatest burden of disease overall, and the fourth worldwide. As the outcome of the widespread impact of depression, antidepressants are now the second most dispensed drug class in the United States, second only to analgesics, which include prescription-free drugs such as aspirin and acetaminophen. Despite immense research for over 60 years, the causes of depression remain unknown and current therapeutic approaches are largely based on hypotheses that are over 40 years old. We further develop here a novel conceptual framework for the underlying biology of the affective, cognitive and systemic manifestation of major depressive disorder (MDD), with the potential to open up new translational pathways for therapeutics.
DEPRESSION AS A DYSREGULATION OF THE STRESS SYSTEM
In a two-part series published in the New England Journal of Medicine in 1988, we presented the concept that major depression represents a dysregulation of the stress system in response to a predisposing, stressful environment. 1, 2 Many studies document that stress precipitates major depression and significantly influences its severity and natural history. [3] [4] [5] We also know that the clinical manifestations and neurobiology of the stress response and affective syndromes such as melancholic depression are very similar, both in their behavioral phenotypes and in their systemic manifestations.
1,2

THE STRESS RESPONSE
The stress response consists of a series of coordinated behavioral and physiological manifestations that promote survival in threatening situations. Anxiety is a foremost feature. The brain has evolved an abundant circuitry for generating anxiety and for the conscious experience of fear. Anxiety and fear-related behaviors are necessary to promote survival during life-threatening situations. Their residues are stored as emotional memories encoded in the amygdala and hippocampus and emerge reflexively during threatening situations, including exposure to social stressors. 6, 7 Cognitive programs shift from those that address complex, sequence-dependent and integrative processes to those that are acquired during previous bouts with danger (reviewed in Gold and Chrousos during which affect is clamped in a distressed state, sleep and food intake are inhibited and there is transient anhedonia, all geared to prevent distraction from danger. 8 During stress and depression, metabolic changes emerge to provide fuel for the brain. These consist of insulin resistance 9 in association with hypothalamic-pituitary-adrenal axis and sympathetic nervous system activations. 10, 11 In addition, there is an activation of the innate immune system, perhaps premonitory response to the threat of a possible injury. We found that medication-free, remitted patients with major depression have increased levels of C-reactive protein and serum amaloid A studied on multiple occasions. 12 We also found increases in multiple coagulation factors, perhaps as a possible priming of the coagulation system as a defense against possible hemorrhage.
13 When these occur due to an accentuated and prolonged stress response, premature systemic disease is the result. Thus, MDD is an independent factor that doubles the risk for coronary heart disease 14 and increases by 60% or more the risk for type 2 diabetes. 15 We also found premature osteoporosis even in premenopausal women. 16 The overall mortality rate in patients with major depression at any age is doubled, independent of suicide, hypertension and smoking, 17 leading to a loss of 7-11 years of life. 18 
DEPRESSION WITH MELANCHOLIC AND ATYPICAL FEATURES MAY REPRESENT DIFFERING FORMS OF STRESS RESPONSE DYSREGULATION
Melancholic depression belies the term depression in that it can be a state of pathological hyperarousal and anxiety, most notably about the self. Melancholic depression prevents the taking of pleasure in what one has achieved or become, enjoyment in everyday life and hopes for the future. Melancholic depression can thus be seen as a state of organized anxiety and anguish that has infiltrated the entire cycle of life, past, present and future. It seems, at times, that patients with melancholic depression are dominated by a preferential access to negatively charged emotional memories without recall of explicit content. 8 Melancholic depression is also associated with diminished concentration, impaired cognitive function and anhedonia. Patients with melancholic depression also manifest evidence of physiological hyperarousal such as hypercortisolism, 19, 20 sympathetic nervous system activation 10, 11 and suppression of the growth hormone 21 and reproductive axes. 22 Patients with melancholia characteristically exhibit insomnia (most often early morning awakening), loss of appetite and loss of interest in sexual activity. Melancholia is associated with a diurnal variation in the severity of depressed mood, which is greatest early in the morning, improving slightly with the passage of the day. We have shown that an early morning surge of plasma norepinephrine accompanies that of cortisol to potentially contribute to this diurnal pattern in mood. 10 As noted, major depression is also a proinflammatory and prothrombotic state, as well as a state of elevated hemoconcentration that is normalized by antidepressant treatment. 23 These features closely resemble many components of the acute stress response occurring for prolonged periods of time.
Although both atypical and melancholic depression are associated with dysphoria and anhedonia, atypical depression has several features that are the antithesis of those found in MDD with melancholic features. Atypical depression is associated with a disturbing sense of disconnectedness and emptiness, punctuated by brief emotional reactions to external circumstances. In contrast to those with melancholic features, who seem to have ready access to negatively charged memories, patients with atypical depression often seem walled off from themselves. They may complain of a cognitive and mental weariness and avoid others, often with the sense that contact would be too demanding, tiring and poorly received. Neurovegetative symptoms in atypical depression are the reverse of those that are found in MDD with melancholic features and consist of lethargy, fatigue, excessive sleepiness, increased food intake, weight gain and worsening as the day progresses. Some forms of atypical depression such as seasonal affective disorder are associated with a hypofunctioning hypothalamic-pituitary-adrenal axis. 24 These features suggest a suppression or burnout of stress system activity.
INTRACELLULAR AND STRUCTURAL CHANGES IN DEPRESSION
For years, depression research has focused on extracellular mediators of the stress response such as corticotropin-releasing hormone (CRH), 25, 26 vascular endothelial growth factor, 27, 28 cortisol and the monoamine neurotransmitters. Recent data have widened the fields of stress and depression research considerably in the consideration of epigenetic factors as well as inflammatory, oxidative and metabolic stressors at the cellular level that may be associated with structural central nervous system (CNS) changes. Patients with MDD have loss of volume, decreased numbers of glial cells and shrinkage of neurons in the subgenual prefrontal cortex. 29, 30 This region contributes to the estimation of the likelihood of punishment and reward, 31 promotes extinction of conditioned fear encoded in the amygdala 7, 31 and confers cortical restraint on the amygdala, the CRH and the locus coeruleusnorepinephrine systems. 29 Cook and Wellman 32 later found that chronic stress of the sort that produces depression-like symptoms in rodents caused significant regression of the apical dendrites of pyramidal cells in the medial prefrontal cortex. MDD patients also have loss of volume in the hippocampus, associated with loss of neuroplasticity consisting of retraction of apical dendrites, decreased neuropil and reduction in dendritic spine density. 33, 34 Glutaminergic excess, which is associated with endoplasmic reticulum (ER) stress, has been implicated in these structural changes. 35 The hippocampus has indirect connections to the ventral tegmental area. It has been hypothesized that this excitatory connection from hippocampus to the ventral tegmental area is critical for the firing of ventral tegmental area cells in response to hedonic stimuli. 36 Impairment of this pathway could therefore be relevant to the anhedonia of depressive illness. The hippocampus also has connections to the prefrontal cortex and amygdala of potential relevance to depression. We found that in response to severe stress, CRH was expressed in the hippocampus, which ordinarily does not express this stress mediator (PW Gold et al., unpublished observations).
In contrast to the findings regarding the hippocampus in depression, increased dendritic length and branching in amygdala and bed nucleus of the stria terminalis have been documented, in association with evidence of an activated amygdala in depression. Taken together, these changes in prefrontal cortex, hippocampus, ventral tegmental area and amygdala can underlie increased anticipation of harm, cognitive impairment, anhedonia, disruption of sleep, decreased appetite and multiple systemic manifestations of depressive illness (vide infra).
Downstream changes in the CRH and locus coeruleusnorepinephrine systems are likely to contribute to the long-term medical consequences of major depression. CRH not only activates the hypothalamic-pituitary-adrenal axis, but also the sympathetic nervous system, as well as exerting important proinflammatory effects, reversible by the administration of the CRH antagonist, antalarmin. In the brain, CRH can be neurotoxic, an effect ameliorated by antagonizing of the CRH receptor 1. 37 Moreover, CRH could also contribute to some phenotypic changes characteristic of melancholic depression. Administration of CRH centrally leads to fear-related behaviors 38 and decreases in appetite, 39 sleep 40 and sexual activity. CRH also suppresses the hypothalamic-pituitary-gonadal axis. 41 We have shown that administration of the CRH receptor 1 antagonist antalarmin significantly reduces stress-induced anxiety in non-human primates, in association with significant reductions in the responses of plasma adrenocorticotropic hormone, norepinephrine and epinephrine, and in the levels of cerebrospinal fluid (CSF) CRH. 42 Recent trials of CRH antagonists in depressive illness have generated negative results, but none of these studies stratified depressive syndromes into those with melancholic or atypical features, potentially obscuring changes that would be expected to occur preferentially in patients with melancholic features.
Neurogenesis in the adult was first described over 60 years ago. 43, 44 A marked cellular effect of several antidepressant medications is the induction of neurogenesis in the adult rodent dentate gyrus of the hippocampus. This neurogenesis was required for responses to antidepressants in several animal models. [45] [46] [47] [48] [49] Other interventions that are reported to promote neurogenesis and ameliorate depression-like behaviors include electroconvulsive treatment (ECT), 50 running 51 and activation of the CNS peroxisome proliferator-activated receptor-g (PPAR-g) system. 52 The mechanisms by which neurogenesis might promote antidepressant effects are unknown. Although several forms of stress reduce hippocampal cell neurogenesis, 45, 47 decreased neurogenesis by itself does not induce anxiety-or depressive-like behaviors. 53 
PARAINFLAMMATION AND ER STRESS: CNS INSULIN, KLOTHO AND PPAR-g SYSTEMS: RELEVANCE TO NEURONAL RESILIENCE IN MDD PATIENTS
We believe that there is in MDD a heretofore unrecognized or at least underrecognized role for two highly interrelated stressrelated processes, parainflammation and ER stress, and three potential modulators of these processes, the CNS insulin, klotho and PPAR-g systems. The CNS insulin, klotho and PPAR-g systems are not only closely linked to parainflammation and ER stress, but also to one another. Optimally, they should help to counteract stress-induced parainflammation and ER stress and should limit the deleterious effects of inflammatory and metabolic changes associated with MDD, thereby promoting an adaptive rather than pathological stress response.
INFLAMMATION IN MDD PATIENTS
Although depression is characterized by multiple systemic manifestations, inflammation has been the primary focus of a prolific literature in depression research (reviewed in Raison et al. 54 ). Patients with major depression have elevated levels of inflammatory cytokines, acute-phase proteins and cellular adhesion molecules indicative of activation of the innate immune system, as reviewed in previous studies. 54, [55] [56] [57] [58] We have found that patients with major depression have levels of plasma interleukin-6 (IL-6) that are elevated around the clock with an abnormal diurnal rhythm 59 and, as noted, that medication-free, remitted MDD patients have increases in the acute-phase proteins C-reactive protein and serum amaloid A measured longitudinally on multiple occasions. 12 In addition, interferon-g administration induces a clear depressive syndrome. 60 Several independent studies in experimental animals have shown that increased plasma levels of peripheral inflammatory mediators, including cytokines that are increased in affective illness, are associated with CNS inflammation. 53, 61 In non-human primates, peripheral infusions of IL-1 increase CSF levels of IL-6, whereas infusions of interferon-g to patients with hepatitis increases CSF IL-6 levels as well (reviewed inRaison et al. 54 ). Cytokines in plasma such as IL-1 or IL-6 bind to receptors in cerebral capillaries that then transduce changes within the brain itself. 62 In addition, CSF cytokine levels are elevated in depression. 61 Although we do not know the extent to which CNS inflammatory mediators relate to the size and functional changes in brain structures likely to be involved in the pathogenesis of affective illness, it may be possible to utilize anti-inflammatory agents or more broadly acting compounds such as insulin, klotho and PPAR-g agonists in the treatment of MDD.
Given the abundant evidence documenting inflammation in patients with depressive illness, the question remains of why is inflammation so prominent in a disease that does not seem overtly like an inflammatory illness. One possibility is that the form of inflammation in depressive illness is that of parainflammation, first proposed and reviewed recently by Medzhitov 63 and subsequently by Hotamisligil. 64 Among the manifestations of parainflammation is a low-level, persistent activation of the acutephase response including compounds such as C-reactive protein and serum amaloid A. 12 
PARAINFLAMMATION
Parainflammation is a tissue adaptive response to noxious stress or malfunction whose physiological purpose is to restore tissue functionality and homeostasis. Parainflammation may become chronic if tissue stress or malfunction persists for a sustained period. It is now believed that chronic parainflammation contributes to the initiation and progression of many human diseases including obesity, type 2 diabetes, atherosclerosis and age-related neurodegenerative disorders. 63, 64 Parainflammation occurs in response to stressors such as overfeeding and aging that were not present during our early evolutionary history, and for which we are not adequately prepared. 63, 64 These also include alterations of the light/dark cycle and exposure to novel foodstuffs and chemicals. As a recent example, Bedrosian et al. 65 have shown that chronic dim light at night provokes a reversible depression-like phenotype, with a possible role for tumor necrosis factor, suggestive of parainflammation. As noted, Medzhitov 63 has proposed that parainflammation is probably responsible for the chronic inflammatory conditions that are associated with modern human diseases resulting from stimuli to which we were not exposed early in our evolution. We extend that concept and hypothesize here that the frequent occurrence of acute or chronic social stressors that go on for extended periods also represents a stimulus to which early humans were not exposed and, hence, major depression is associated with a parainflammatory state.
The difference between classical inflammation and parainflammation is that the latter does not occur in response to pathogens or tissue damage, but rather from alterations in the homeostatic set point in specific tissues in response to stressors such as those involving nutrient sensing, energy metabolism, oxidant burden, endocrine regulation and autonomic stability ( Figure 1 ). 63 Parainflammatory mediators have effects beyond those on inflammatory phenomena and help coordinate endocrine, metabolic and autonomic activity as well. In the periphery, parainflammatory phenomena are handled, in part, by tissue-resident macrophages and mast cells that are among the key mediators of the innate immune response and illnesses such as atherosclerosis. 64, 66 We postulate that illnesses that are associated with a chronic activation of the innate immune system in the absence of a pathogenic trigger or an injury are likely to be manifestations of parainflammation.
In advanced parainflammation, individual cells cannot take care of the alterations in homeostatic set point. Therefore, advanced parainflammation involves not only individual cells, but also a tissue entity of varying size such as the endothelium. Consequently, an entire tissue participates in a response to resident macrophages or mast cells, and sends a signal for activation of the acute-phase response. Depending on the degree, inflammatory monocytes or other components may be recruited from the circulation, involving principally the innate immune system (Figure1). 63 In the CNS, parainflammation may also occur in response to the same stimuli that activate parainflammation in the periphery. In the section on CNS insulin, we cite data regarding the capacity of overfeeding to initiate a CNS inflammatory response mediated by nuclear factor-kB (NF-kB) and the ER stress response in the medial basal hypothalamus. 67 A very notable finding of this study was that the CNS changes must occur before the onset of peripheral insulin resistance. If either overfeeding-induced NF-kB or the ER stress response in medial basal hypothalamus were blocked, peripheral insulin resistance did not follow. 67 In summary, there are multiple reasons for inflammation in depressive illness. As noted, the stress system response, activated in depression, is itself characterized by a proinflammatory response, perhaps in anticipation of injury. In addition, depression is a disease associated with parainflammation. Moreover, inflammatory mediators, such as cytokines, play key roles in metabolism and metabolic rate, autonomic activity and behaviors such as cautious avoidance, which illustrate their pleiotropy and nonspecificity. Parainflammation and ER stress often occur together.
ER STRESS: A LIFE AND DEATH MATTER
One of the principal roles of ER is the proper folding of proteins to render them appropriate for delivery to the cytoplasm. Multiple Figure 1 . Inflammation and the stress response: inflammation is an adaptive response to noxious conditions. (a) Under normal condition, tissue-resident macrophages maintain tissue homeostasis by removing dead cells and other debris and by producing growth factors. (b) Under noxious conditions, the cellular stress response is activated and results in a cell autonomous adaption. It may, however, also involve communication between stressed cells and other cells in the tissue environment, including resident macrophages. In the paper by Zhang, overfeeding resulted in parainflammation associated with a cell autonomous expression of nuclear factor-kB (NF-kB) in cells of the medial basal hypothalamus, in association with endoplasmic reticulum (ER) stress. (c) If the nature of the extent of the stress is such that it affects not only individual cells but an entire tissue (for example, hypoxia or hyperthermia), then a tissue level stress response is elicited by resident macrophages (and in some tissues by mast cells). In this form of parainflammation, depending on the degree of the inciting stimulus, this response can involve the recruitment of different types of inflammatory monocytes from the circulation. Parainflammation may also involve low-level release of plasma components into the affected tissue. (d) Beyond parainflammation. If the stimulus is severe enough (for example, infection or injury), then a classic acute inflammatory response occurs. Parainflammation is inflammation that occurs in the absence of a known infection or injury, but in response to stimuli to which we were not exposed during our early evolution. The classic inflammatory response is characterized by the recruitment of neutrophils and specialized subsets of monocytes from the circulation that help to protect the host from infection and promote tissue repair and restoration of homeostasis. Here, only a few examples of inflammatory mediators are shown. Adapted from Zhang. 67 physiological or pathological conditions that affect protein folding or overload the capacity of ER to fold proteins can cause ER stress, the term given to an imbalance between the cellular demand for ER function and ER capacity. For example, increased glutamate stimulation that leads to elevated protein synthesis that exceeds the capacity of ER for effective protein folding is one of the many stimuli that can cause ER stress. 64, [68] [69] [70] [71] Overfeeding causes ER stress in the CNS. 67 Cells respond to ER stress with the ER stress response (also known as the unfolded protein response) by promoting the production of chaperones, attenuating translation, setting into motion the ER stress-associated degradation response for the degradation of unfolded proteins as well as promoting protein folding and secretion. 64 If the ER stress response can fully address the challenge so that only normal proteins are produced, the cell survives. 71 If residual unfolded proteins remain that would be released as mutant proteins, a specific apoptotic response occurs, in association with substantial transport of calcium from the ER into the cytoplasm. 72, 73, 74 The ER contains the largest reservoir of calcium in the cell.
Two proteins play a key role in the release of Ca þ from the ER: ERO-1a and the calcium channel IP3R. The antiapoptotic protein B-cell lymphoma 2 (Bcl-2) inhibits ER stress-induced calcium release via inhibition of the IP3R calcium channel. 71, 72, 74, 75 The ER stress response is regulated by three principal branches: IRE1, PERK and ATF6 (Figure 2) . 64 ATF6 is one of the mediators that leads directly to the production of chaperones and the activation of X-box binding protein 1 (XBP-1). XBP-1, in turn, also activates the production of chaperones as well as the stimulation of the protein degradation response. PERK leads to inhibition of translation as well as the activation of CHOP, which promotes release of calcium into the cytoplasm and subsequent apoptosis (Figure 2 ). Mood stabilizers influence many of these processes (vide infra).
Impaired intracellular calcium regulation is among the bestdocumented abnormalities in bipolar disorder. Machado-Vieira et al. 76 found that compared with bipolar patients with the GG variant of the Bcl-2 genes, bipolar patients with the Bcl-2 variant AA had higher lymphoblastic cytosolic calcium concentrations. These subjects also had a significantly greater increase in cytosolic calcium concentrations in lymphoblasts following stimulation with the IP3R agonist AdA. 76 A likely source for the increased intracellular calcium is the ER, which contains the largest reservoir of calcium in the cell and which, as noted, releases calcium into the cytoplasm when it cannot adequately resolve the problem of an excess of unfolded proteins. In the study by Machado-Vieira et al., 76 the basal intracellular calcium concentration showed a significant negative correlation with Bcl-2 mRNA expression and protein. Moreover, a Bcl-2 inhibitor given to those with GG led to cytosolic calcium concentrations similar to those in the AA variant group. It should be noted, however, that although the results suggest that the AA polymorphism is a candidate for a risk allele in bipolar disorder, similar genotype-specific calcium dysregulation has been reported with those for the GG variant, suggesting that the GG variant is not causal. 76 Several stimuli can promote the overproduction of proteins that activate the ER stress response in the CNS. These include parainflammatory stimuli such as overfeeding. 67 As noted, neuronal hyperstimulation by glutamate can also lead to ER stress by increasing neuronal gene expression and translation. 77 Activation of elements that encode compounds like the ER stress protein GRP78 protects from glutamate-induced neurotoxicity and XP1 is crucial for the ERAD program and for production of multiple chaperones, whereas GRP78 is a key chaperone that is deployed early in the ER stress response. Valproate exerts multiple effects to influence the ER response in favor of cell rescue. These effects occur, in part, via stimulation of the ATF6 branch of the ER stress response. ATF6 is the gene upstream of XBP-1 and is a potent stimulus to XBP-1 expression. Valproate may also exert a stimulatory effect on the production of chaperones and on the ERAD response independent of its effect on ATF6. Lithium also exerts multiple effects on the ER response in favor of cell rescue. Lithium promotes the expression of chaperones and Bcl-2. Both valproate and lithium inactivate glycogen synthase kinase 3 (GSK-3), which transduces many downstream effects that occur in the context of activation of the ER stress response, leading to apoptosis. Adapted from Hotamisligil. 64 other causes of a pathologic ER stress response. 77 GRP78 activation occurs early in the ER stress response where it serves as a sensor that activates the ER stress response and also serves as an ER stress chaperone. Inhibiting dephosphorylation of the key ER stress mediator Elf2a by salubrinal prevents glutamatemediated neurotoxicity. 78 In addition, overexpression of the ER molecular chaperone (ORP150) rescues hippocampal neurons from glutamate toxicity, 77, 78 whereas treatment with antisense to GRP-78 leads to increased cell death in response to glutamate or oxidative stress. 72, 74 ER stress is involved in disease states because it can lead to cell death or compromise of cellular resilience. 73, 79 Inappropriate activation of the ER stress response may also be harmful by killing the cell or, alternatively, by protecting the cell from death (for example, during neoplastic transformation or viral infection). 79 The stress response also plays important roles in numerous human pathophysiological processes caused by protein misfolding and retention in the ER, organismal responses to viral infections, malignancy, neurodegeneration, atherosclerosis and type 2 diabetes. 63, 64, 70, 71, 73, [79] [80] [81] [82] We also postulate that a failed ER stress response plays an important role in the depressive syndrome, in part by leading to cell loss or decreased cellular resiliency. Trials targeting ER stress represent a conceptually novel approach to the treatment not only of type 2 diabetes and atherosclerosis, but also of MDD.
RELEVANCE OF ER STRESS TO MAJOR DEPRESSION AND BIPOLAR DISORDER: ASSOCIATION STUDIES, IMPACT OF GENES, MOOD STABILIZERS AND THE REGULATION OF INTRACELLULAR CALCIUM
A polymorphism of the XPB-1 gene is associated with bipolar disorder and leads to a marked decrease in the expression of the XBP-1 and GPR78 genes. 83 As noted, the XBP-1 gene plays a key role in activating the production of multiple chaperones and in the stimulation of ER stress-associated degradation 71, 79 ( Figure 2 ). XBP-1 also participates in the maturation of proteins. The brainderived neurotrophic factor induces XBP-1 activity, and neurite outgrowth is significantly inhibited in XBP-1 À / À neurons. 84 Valproate, a key mood stabilizer in bipolar disorder, influences the ER stress response in favor of cell rescue. A major factor in valproate's activation of an adaptive ER stress response is its capacity to induce ATF6, the gene upstream of XBP-1 and a potent stimulus to XBP-1 expression. Valproate induces the expression of multiple chaperones and the ER stress-associated degradation program. It is unclear the extent to which these effects reflect valproates's effect on ATF6 and which effects are ATF6 independent. Many of the effects of valproate on the expression of these genes in the brain can be detected in both the cerebral cortex and hippocampus. 85, 86 Valproate as well as lithium lead to histone deacetylase inhibition to exert neuroprotective effects. 85 The capacity of valproate to increase the chaperone GRP78 is dependent on its capacity to inhibit histone deacetylase. Valproate also induces WFS1 expression and modulates its interaction with ER stress protein GRP94. 87 Mutation of the WFS1 protein leads to Wolfram's syndrome, an illness associated with ER stress and a high incidence of serious affective illness.
Valproate directly inactivates glycogen synthase kinase 3 (GSK-3). One impact of this inhibition is protection of cells from ER stress-induced accumulation of intracellular lipids and inhibition of apoptosis 88 In general, inactivation of GSK-3 has many other salutary effects on neuronal resilience, including secretion of nerve growth factors, facilitation of axonal growth, facilitating assembly of cytoskeletal protein in axons 89 and inhibition of apoptosis by multiple mechanisms. 89 The ER stress response is modulated by lithium in favor of cell rescue as well. Lithium is one of the best-characterized inhibitors of GSK-3 in the CNS. 90 In addition, lithium inhibits the ER calcium channel IP3R, and hence ER stress-induced release of calcium into the cytoplasm. Lithium also enhances the adaptive capacity of the ER stress response by promoting the expression of GRP78 and Bcl-2.
91 Lithium also increases the expression of GRP94, a chaperone that is coordinately regulated with GRP78 and has antiapoptotic effects. Both GRP78 and GRP94 are located in the ER membrane and act early to facilitate the effective folding of newly synthesized proteins entering the ER. Enhancing the effectiveness of the ER stress response had been shown not only to diminish glutamate-induced neural dysfunctions, but also to reverse the depressogenic effects of serotonin and norepinephrine depletion, and to protect against the learned helplessness paradigm. Enhancement of BI-1 expression contributes to these effects.
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AMELIORATION OF PARAINFLAMMATION OR A PATHOLOGIC ER STRESS RESPONSE: THE CNS INSULIN, KLOTHO AND PPAR-g SYSTEMS
We include three highly interrelated CNS systems of relevance to parainflammation and ER stress: the CNS insulin, klotho and PPAR-g systems. We postulate that these systems promote amelioration of parainflammation and a pathologic endoplasmic stress response, as well as relief of associated increased burdens of CNS inflammatory, metabolic and oxidative stressors.
CNS INSULIN, A KEY REGULATOR OF NEURONAL PLASTICITY AND NEURONAL RESISTANCE TO STRESS: AN OVERVIEW
Multiple studies report that patients with major depression are insulin resistant. [95] [96] [97] [98] Recent data in experimental animals indicate that peripheral insulin resistance in response to overfeeding occurs only after CNS changes first present. 67 Moreover, the peripheral insulin resistance does not occur if these CNS changes are antagonized (vide infra). Other studies report that a diet high in fat produces insulin resistance in the brain, [99] [100] [101] whereas changes originating in the brain can influence either insulin resistance or insulin sensitivity in the periphery [102] [103] [104] [105] (vide infra). Insulin also plays a major role in support of neuroplasticity, [106] [107] [108] [109] [110] [111] and in the passage of glucose into neurons susceptible to hypoglycemia. [112] [113] Sources of insulin in the brain Insulin in the brain derives principally from peripherally circulating insulin. 114 Insulin is conveyed into the CNS by binding to insulin receptors in the blood brain barrier for subsequent transport into brain. 115 Multiple models have shown that increased plasma levels of insulin are associated with decreased CNS insulin levels secondary to saturation of blood brain barrier insulin receptors. [116] [117] [118] Glucocorticoid excess reduces the transport of insulin from the periphery into the brain. 119 Distribution of insulin receptors in the brain Although insulin receptors are abundant in the brain, they are selectively distributed and preferentially localized in synaptic membranes. 106, 107 In rodents, insulin binding is highest in the olfactory bulb, cerebral cortex, hippocampus, hypothalamus, amygdala and septum. Insulin receptors are also concentrated in the substantia nigra, basal ganglia and frontal cortex. 108 Insulin resistance, present in depression, must first occur in the brain, before it is manifested peripherally In the landmark study by Zhang et al., 67 overfeeding in mice resulted in activation of the NF-kB system in neurons of the medial basal hypothalamus even before weight gain occurred. The NF-kB activation occurred without activation by inflammatory mediators released from surrounding cells that ordinarily bind to the neuronal membrane, thus representing an intraneuronal, autonomous activation of NF-kB. The NF-kB response was also accompanied by activation of the ER stress response and insulin resistance. 67 When NF-kB activation or the ER stress response was prevented in overfed mice, either genetically, via viral vector, or by interference with the ER stress response, central insulin resistance resolved and peripheral insulin resistance did not occur. 67 Moreover, blockade of the ER stress response also prevented the expression of NF-kB in the medial basal hypothalamus. Therefore, the classic stimulus to peripheral insulin resistance, overfeeding, requires prior changes in the brain before it becomes apparent in the periphery. 67 Several other studies further documented CNS modulation of peripheral insulin resistance by a number of disparate mechanisms. [99] [100] [101] [102] [103] [104] [105] For example, De Souza et al. 99 noted that after prolonged feeding of a high-fat diet, parainflammation had progressed with not only expression of NF-kB in the hypothalamus, but also of IL-1b, tumor necrosis factor-a and IL-6 (the three key components characteristic of the innate immune response and of parainflammation). Posey et al. 100 also found that overfeeding produced hypothalamic proinflammatory lipid accumulation and insulin resistance.
Conversely, Koch et al. 101 showed that activation of CNS insulin receptors increased gluconeogenesis and, hence, glucose storage in the liver, thereby significantly improving insulin sensitivity. Gelling et al. 102 found that insulin action in the brain contributes to glucose lowering during insulin treatment of diabetes. Brainderived neurotrophic factor improves blood glucose control in diabetic rats. 103 Yue and Lam 104 elucidate the relationship between CNS lipid sensing and insulin resistance in the brain, whereas Schwartz and Porte 105 provide an integration regarding some aspects of the extent to which neural systems regulate energy intake, energy expenditure and endogenous glucose production.
These data represent further evidence indicating that CNS changes either precede the onset of peripheral insulin resistance in the context of overfeeding or can independently influence insulin sensitivity in the periphery.
CNS insulin, neuroplasticity and neuroprotection Chiu et al. 106 published the first in vivo demonstration that brain insulin contributes to processing of sensory information and adjusting the plasticity of brain circuits to new experience, thus incorporating neurons into new circuits. Insulin receptor signaling correlated with the density of synapses, insulin receptors maintain synaptic density and synapse density decreases when insulin receptors are removed or are dysfunctional. 106 Insulin has been shown to play a particularly important role in neuroplasticity in the hippocampus and elsewhere via the insulin receptor substrate p53 (IRSp53). [107] [108] [109] [110] [111] IRSp53 is widely distributed in the CNS and is found preferentially in synaptic locations in the cortex, hippocampus and cerebellum. [106] [107] [108] Structural, biochemical and cell biological experiments support the unique role of this family as transducers of signaling, linking the protruding membrane to the reorganization of the underlying actin cytoskeleton. [109] [110] The mechanism of IRSp53-mediated neuroplasticity is thought to involve activation of the migration of actin fibrils to the terminals of neuronal dendrites, which bring with them key informational substances relevant to effective neuroplasticity. A key paper in this area reported that RNA-mediated knockdown of the IRSp53 gene expression severely impaired learning and memory and led to significant shrinkage of dendritic projections, whereas overexpression of IRSp53 led to increased density of dendritic spines.
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IRSp53 is critical for transporting glucose across dendritic terminals via GLUT3, GLUT4 112 and GLUT5. 113 This type of glucose transport occurs in neurons that are subject to excessive metabolic demands and that are particularly sensitive to hypoglycemia. These include hippocampus and forebrain cholinergic neurons. The administration of corticosterone impairs insulin-stimulated GLUT4 in the rat hippocampus, suggesting that glucoprivation could be one of the several mechanisms involved in the decreased hippocampal size in depression.
Insulin resistance and ER stress are highly interrelated. 81,120 ER stress promotes insulin resistance, whereas insulin resistance exacerbates ER stress, thereby setting up a vicious cycle. Further linkage between ER stress and the insulin system derives from studies showing that reduced insulin signaling is associated with increased intracellular calcium levels, whereas increased intracellular calcium concentrations decrease insulin signaling. 121 Insulin and CNS disease: Alzheimer's disease and other neurodegenerative diseases Patients with Alzheimer's disease have increased plasma insulin levels, reduced CSF insulin levels and a decrease of insulin receptors in the brain. Reduced brain insulin signaling is associated with tau phosphorylation and amyloid-b (Ab) levels in a streptotoztocin mouse model of diabetes. Insulin also promotes the release of intracellular Ab in neuronal cultures and accelerates Ab trafficking to the plasma membrane. [122] [123] [124] The extent to which peripheral insulin resistance in patients with Alzheimer's disease is related to the apparent dysfunction of insulin in the CNS of Alzheimer's patients is unknown. As noted earlier, data from several populations of patients with peripheral insulin resistance and hyperinsulinemia have reduced CSF insulin levels, presumably because of downregulation of blood brain barrier insulin receptors. 122 Intravenous insulin infusion increased levels of Ab42 in the CSF of both controls and patients with Alzheimer's disease. 123 Patients with type 2 diabetes have a significant increase in Alzheimer's disease thought to be independent of the vascular complications of diabetes. 124 Patients with depressive illness also have an increased incidence of Alzheimer's disease.
Parkinson's disease, amyotrophic lateral sclerosis and Friedrich's ataxia In Parkinson's disease, selective neuronal loss in the substantia nigra is accompanied by decreased immunoreactivity of the insulin receptor as determined using immunohistochemical studies. Parkinson's disease patients also have insulin resistance and decreased CSF insulin levels. 124 Insulin is also thought to play roles in the pathogenesis of amyotrophic lateral sclerosis, multiple sclerosis and Friedrich's ataxia. The NIH (National Institutes of Health) is now conducting several trials of the insulin receptor sensitizer, pioglitazone, in patients with multiple sclerosis (NCT00242177), Friedrich's ataxia (NCT00811681), amyotrophic lateral sclerosis (NCT00690118) and Alzheimer's disease (NCT00982202).
CNS insulin effects on lifespan
In drosophila, the homolog of insulin (DAF1) is produced by neurons and modulates lifespan, metabolic activity and reproductive function. Food deprivation downregulates the drosophila insulin homolog, setting into motion the Dauer stage, characterized by a pronounced slowing of metabolism and oxidative stress, inhibition of reproduction and lengthening lifespan significantly, despite a diabetic phenotype. This phenomenon also occurs with the ablation of insulin neurons in drosophila. 125 The mechanism is thought to involve, in part, removal of insulin-induced inhibition of the FOXO1 gene, leading to an increase in the expression of antiaging genes such as the antioxidants catalase, glutathione, superoxide dismutase, glutathione, metallothionein, chaperones (HSP-16) and metabolic genes (for example, apolipoproteins).
On the surface, these results contradict the data that in mammals CNS insulin promotes neuroplasticity and confers protection against the adverse sequella of oxidative stress, while enhancing cognitive function. However, it should be noted that downstream insulin events are transduced by multiple insulin response substrates, multiple isomers of second messenger systems and a host of other mediators that alter gene function, prompting Russel and Kahn. 126 to estimate that an activation of the insulin receptor could lead to 288 possibilities of gene expression. In addition, the FOXO system consists of many homologous genes in mammals, though only 1 (DAF16) in drosophila. Different FOXO genes have differing brain localizations. Moreover, in humans, different FOXO genes have been linked to the initiation of apoptosis or neuronal survival.
Taguchi et al. 127 studied brain-specific IRS-1 knockout mice and found that the lifespan increased by B20%. However, these mice had a 30% reduction in brain weight, which is likely to be associated with significant cognitive impairment. Selman et al.
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studied total-body IRS-1 and IRS-2 knockout mice and found that the IRS-1 knockout mice had significant life extension, whereas the lifespan of IRS-2 knockout mice was significantly reduced. Other than the fact that the IRS-1 knockout was brain specific in the first study, no conclusion can be drawn from these disparate findings.
As in the periphery, insulin in brain exerts effects through multiple pathways including the phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways. The phosphatidylinositol 3-kinase pathway has been shown to mediate the neuroplastic and neuroprotective changes of insulin and its salutary effects on cognition. The downstream mediators that are involved in the insulin-induced affect on lifespan have not yet been definitively determined, but could involve the mitogenactivated protein kinase system.
Taken together, the effect of CNS insulin in the enhancement of neuroplasticity, anti-inflammatory actions and amelioration of the burden of oxidative stress suggest that CNS insulin may be an appropriate target for the treatment of depressive illness.
KLOTHO
The name klotho is derived from the Greek goddess who spins the web of time. Klotho is the only single gene now known to significantly extend life. Klotho-deficient mice have decreased lifespan and multiple premature senescent phenotypes. 129 These senescent phenotypes resemble those in major depression and include premature coronary artery disease and premature osteoporosis. Klotho-deficient mice have a decreased synaptic density in the hippocampus as a reflection of increased oxidative stress in the hippocampus, 130 and pronounced memory deficits that are corrected by klotho administration or gene transfer. 131 Klotho-deficient mice also show a pronounced deficiency of the nitric oxide system with resultant widespread endothelial pathology reversed by the administration of klotho. 132 Klotho-deficient mice have a generalized increase in the overall burden of oxidative stress throughout the CNS. 133 Klotho exerts brain-wide anti-oxidative and anti-inflammatory effects. 130, 131 Klotho decreases parainflammation and improves the efficiency of the ER stress response. In addition, Klotho modulates CNS calcium metabolism, in part, by mediation of the transport of calcium across the blood brain barrier. 134 Klotho affects transient voltage potential dependent receptors in the brain involved in CSF formation. 135 In the CNS, klotho is produced exclusively by apical ependymal cells that lie adjacent to the subventrivular zone, 136 which is one of two sites that produce neural stem cells. Klotho is secreted directly into the CSF, which is the communication pathway for its biological actions in the brain.
In the periphery, klotho is synthesized primarily in the kidney 136 and, like klotho in the CNS, circulates as a hormone as well. 136 In the periphery, klotho has pronounced systemic antioxidative effects as well and has a pronounced effect in enhancing the activity of nitric oxide in blood vessels. Klotho administration to klotho-deficient mice significantly diminishes the oxidation burden and corrects pronounced endothelial dysfunction. Like the CNS insulin system, klotho is also a potential target for the treatment of affective illness.
THE PPAR-g SYSTEM Clinicians first used PPAR-g agonists in clinical medicine for the treatment of insulin resistance and type 2 diabetes, based on their capacity to sensitize insulin receptors. Subsequent studies revealed that associated with increased insulin sensitivity, PPARg administration led to improvements in inflammation, dyslipidemia, hypercoagulation and hypertension (Figure 3) . 137 As hyperinsulinemia itself can lead to all of these changes, amelioration of these stigmata could reflect the secondary impact of the normalization of elevated plasma insulin levels. In patients on the verge of type 2 diabetes, PPAR-g administration prevented the transition to type 2 diabetes, in part, based on their capacity to diminish the ER stress response in pancreatic b-cells.
It should be noted that inflammation itself can diminish the sensitivity of insulin receptors and contribute to hypercoagulation, hypertension, dyslipidemia and increases in blood pressure. 138 It is thus possible that the anti-inflammatory effects of PPAR-g could lead to its capacity to increase insulin sensitivity and to treat other stigmata of the insulin-resistance syndrome. The impact of PPAR-g agonist effects on insulin resistance syndrome is shown schematically in Figure 3 .
In the brain, PPAR-g receptor is a nuclear receptor found in neurons, glia and cerebrovascular vessels in the frontal cortex, nucleus accumbens, striatum, hippocampus, hypothalamus and substantia nigra. 139 The PPAR-g system is found in neurons, glial cells and cerebrovascular endothelial cells. Figure 3 . Decreased physical activity, excessive food intake and genetic background predispose to obesity. The genetic background also contributes to the risk that obesity will result in insulin resistance as a precursor to type 2 diabetes. PPAR-g agonists significantly protect from the stigmata of the insulin resistance syndrome and significantly improve hyperglycemia, dyslipidemia, hyperinsulinism, inflammation, hypercoagulation and hypertension. PPAR-g agonists also help prevent the conversion to type 2 diabetes by promoting an adaptive endoplasmic reticulum (ER) stress response rather than one that leads to apoptosis.
Through multiple mechanisms, the PPAR-g system in brain rapidly senses CNS cellular stress and responds to ameliorate it. [140] [141] [142] [143] [144] [145] [146] [147] [148] [149] [150] [151] [152] [153] Many overlapping mechanisms contribute to the neuroprotection afforded by the PPAR-g system.
The PPAR-g system provides protection against multiple mediators of the innate immune system including NF-kB, tumor necrosis factor-a, interferon-g, IL-1b, as well as COX2, MCP1 and VCAM1. [141] [142] [143] In addition to these anti-inflammatory effects, the PPAR-g system affords protection from oxidative stress via Bcl-2 upregulation by PPAR-g agonists. 144 ,145 PPAR-g also affords protection from destructive ER stress as evidenced by rescue of pancreatic islet cell function through reduction of severe ER stress. 146 Accordingly, clinical studies report that the PPAR-g agonist piaglitizone helps to avert the onset of type 2 diabetes.
PPAR-g antagonists provide neuroprotective coverage from glutamate toxicity in multiple settings, acting for as long as 2.5 h after glutaminergic stress, a time interval longer than for any specific glutamate receptor antagonist. 147, 148 In the study by Festuccia et al., 149 PPAR-g agonists also inhibit the neurotoxic effects of norepinephrine and glucocorticoid excess.
A potentially important mechanism for the neuroprotective effect of PPAR-g reflects its capacity to promote neurogenesis during periods of neuronal stress. 52 The PPAR-g system is involved in pathways that participate in the control of the proliferation, migration and differentiation of neural stem cells. These include the Wnt, STAT3 and NF-kB signaling systems. 52 PPAR-g is a key driver of longevity in the rat. Argmann et al. 150 established a transcriptional network representing thus-farunknown longevity genes. The PPAR-g signaling pathway and the transcriptional signature of a PPAR-g agonist rosiglitazone overlapped. In support of a role for PPAR-g in longevity, the lifespan of PPAR-g À / À mice was significantly reduced. To determine the extent to which klotho might be involved in this PPAR-g-mediated longevity, Zhang et al. 151 found that PPAR-g agonists increased both klotho mRNA and protein expressions in HEK 293 and renal epithelial lines. This induction was blocked by PPAR-g antagonists and by small interfering RNA-mediated gene silencing of PPAR-g. This paper identified a noncanonical PPAR-g response element within the 5 0 flanking region of the human klotho gene, a finding confirmed by studies of transcriptional functionality. These papers indicate that future studies should take into account both the PPAR-g and klotho pathways together in animal models of longevity. 152 In summary, the PPAR-g system plays a role in the regulation of neuroplasticity, neurogenesis, inflammation, the control of free oxygen radicals, glutamate toxicity and the regulation of ER stress (Figure 4) . Hence, it may be a target system for the treatment of depressive illness. Data in experimental animals demonstrate an antidepressant-like effect of compounds that exert an excitatory effect on the PPAR-g system. 153 
CONCLUSION
We have discussed some of the extracellular and intracellular mediators that may contribute to the loss of resilience of neurons in the CNS and have proposed that parainflammation and ER stress play key roles in this pathophysiology. Novel translational pathways are identified for the treatment of depression. Based on our hypotheses, compounds that target parainflammation and the ER stress response, such as those of the insulin, klotho and PPAR-g systems, may represent novel translational approaches for MDD and related conditions. . Repeated social and other stressors plus genetic predisposition lead to decreased neuronal resilience that can, in turn lead to depression. Processes set into motion include parainflammation, extreme endoplasmic reticulum (ER) stress responses, glutamate toxicity, pathologic oxidation, decreased neuroplasticity and deficient neurogenesis. The PPAR-g system can modulate and diminish each of these pathologic drivers.
